BUD vs IKT
BUD (BUD) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
BUD (BUD) common stock.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
BUD does not have a complete income-statement cache yet.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
BUD currently screens at market cap $0. IKT currently screens at market cap $215.2M.
Not investment advice. Open the BUD and IKT stock pages for the full models.
Not investment advice.